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ABSTRACT 
 
Objective:  To investigate the relationship between cortisol levels, pain intensity and negative 
mood in chronic pain patients participating in a multidisciplinary pain management 
programme. 
  
Patients: Eighteen chronic pain patients collected saliva samples over several days both 
directly before and after attending a four-week multidisciplinary pain management 
programme. 
   
Outcome measures: Saliva samples were assayed for their cortisol concentration. Participants 
also completed self-report measures of pain intensity and depression.  
 
Results: Usual pain intensity and waking cortisol levels changed in parallel following 
treatment, as did changes in depression and cortisol levels late in the morning and in the 
evening. Depression did not mediate the association between cortisol and usual pain 
intensity; neither did pain intensity moderate the association between cortisol and depression. 
 
Conclusions: Changes in cortisol secretion may provide a useful biological marker of 
treatment outcome in chronic pain patients after their participation in a multidisciplinary pain 
management programme. 
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INTRODUCTION 
 
Pain that persists despite the application of conventional medical and surgical treatments is 
disruptive not only in physical terms, but also in broader financial, social and emotional 
contexts.  The psychological and social consequences of chronic pain and disability may 
evoke a persistent stress response, perhaps exacerbating or maintaining pain [1]. 
 
 
The stress response involves activation of the sympathetic nervous system and the 
hypothalamic-pituitary-adrenal (HPA) axis. Any physical or psychological threat to 
homeostasis triggers release of corticotrophin-releasing hormone in the hypothalamus, and 
ultimately raises levels of steroid hormones such as cortisol in the blood stream and saliva [2, 
3]. In the short-term, cortisol helps to meet the demands of stress by mobilizing energy stores, 
and assists recovery from stress by inhibiting further release of corticotrophin-releasing 
hormone. However, continuing stress promotes maladaptive functioning of the HPA axis 
which, in turn, may compromise metabolism, impair immune function and alter 
cardiovascular control [4].  
 
In an early study by Shenkin [5], serum cortisol levels were elevated in patients with pain of a 
clearly organic etiology but not in patients with pain of a “psychoneurotic or feigned origin” 
(p1112).  The implication of these findings was that cortisol could be used as an indicator of 
malingering. However, this view remains controversial [6-8]. For example, Lascelles et al. 
[6] reported that serum cortisol levels were elevated in chronic pain patients, regardless of the 
etiology of pain.  In contrast, salivary cortisol levels after awakening were found to be lower 
in patients with persistent sciatic pain eight weeks after discectomy than in pain-free subjects 
[9].  Tennant and Hermann [10] reported that serum cortisol levels varied widely in patients 
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about to participate in a 90-day unimodal opioid treatment program for chronic pain, but 
normalized following treatment in the majority of participants.  The etiology of the shift in 
cortisol levels is uncertain, because the relationship between cortisol levels, pain and other 
psychosocial factors was not investigated. 
 
Chronic pain is associated with an array of psychopathology, including depressive disorders, 
anxiety, personality disorders and substance abuse [11]. For example, the prevalence of major 
depression in chronic pain patients ranges between 30% and 54% [12]. Major depression is 
associated with elevated cortisol levels [13], as is negative affect in general [14]. This 
elevation appears to be driven by stress-induced hypersecretion of corticotrophin-releasing 
hormone, coupled with failure of negative feedback controls to limit the cortisol response 
[15]. Thus, cortisol levels might be elevated in a subgroup of chronic pain patients due to 
depression rather than pain [16]. However, this issue remains unresolved.  
 
The aim of the present study was to investigate the association between cortisol levels, usual 
pain intensity and depression over the course of a multidisciplinary pain management 
programme that incorporated cognitive-behavioural techniques to reduce psychological stress 
[17-19]. In general, reductions in stress and negative affect during various forms of relaxation 
therapy are associated with reductions in cortisol, both in normal and clinical populations 
[20-23].  Thus, we hypothesized that decreases in pain and depression following 
psychological treatment would be associated with decreases in cortisol secretion in chronic 
pain patients. The longitudinal approach adopted in this study has advantages over a standard 
cross-sectional design because it allowed us to investigate changes in key variables 
prospectively. Moreover, we were able to control for the effects of nonspecific aspects of the 
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procedure, such as anticipatory anxiety or multiple sampling, by comparing changes in 
cortisol secretion over the course of treatment with changes in pain and depression.  
 
In most previous studies of chronic pain patients [5-8, 10], cortisol concentrations were 
measured in serum samples. Unfortunately, however, the venesection stress associated with 
obtaining serum could influence results obtained by this method [24, 25].  Saliva, which 
contains only the unbound, biologically active “free” fraction of cortisol, is now accepted as a 
better source for testing cortisol effects than blood [24, 25].  An additional limitation of most 
previous studies is that samples were obtained during a single day of testing [5-9].  As 
cortisol is sensitive to random stressful incidents, cortisol should be sampled over several 
days to average out the impact of these random stressors.  Thus, in the present study, salivary 
samples were obtained for several days before and after patients participated in a 
multidisciplinary treatment programme for chronic pain.   
 
METHODS 
 
Participants were recruited on a voluntary basis after their referral and initial assessment for 
inclusion in the pain management programme.  Participants using strong opioid medications 
or who had received cortisone injections in the previous month were excluded from the study. 
Twenty-one patients agreed to participate but two dropped out of the study while remaining 
in the pain management programme.  Most participants provided at least 90% of the required 
saliva samples.  However, one participant provided less than 50% of the samples, and thus 
was excluded from the study.  Therefore, a final sample of 18 participants (10 females) 
completed the study, ranging in age from 18 to 76 years (mean age 44 years) and a median 
duration of pain of 2.25 years. Fifteen patients suffered from low back, pelvic, neck or 
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shoulder pain, two had rheumatoid arthritis, and another had post-herpetic neuralgia, thus 
composing a fairly heterogenous sample. All but four of the patients who entered the study 
took a range of analgesic, anti-depressant, anti-inflammatory or benzodiazepine medications, 
and three of the participants were smokers. Participants provided their written informed 
consent for the procedures, which were approved by the hospital and university ethics 
committees. 
 
The pain management programme ran for four weeks, with participants attending each 
weekday morning.  Participants attended 2-hour physiotherapy classes each day, consisting of 
graded exercises such as stretching and walking.  They also attended 1-hour 
psychoeducational seminars twice each week covering topics including medical and 
psychological information, stress management, cognitive coping techniques, and lifestyle 
adjustment.  In addition, participants attended three 1-hour relaxation training sessions during 
the programme, and had access to individual psychotherapy as required. An evaluation of the 
programme in a prospective controlled cohort study indicated that gains were made in terms 
of depression, disability and pain [17]. 
 
Pain perception was assessed using a simple 0 (no pain at all) to 10 (worst pain imaginable) 
Numerical Graphic Rating Scale (NGRS) of usual pain intensity, while depression was 
assessed using the Zung Self-Rating Depression Scale (ZSDS) [26, 27].  In addition, 
participants completed the Roland-Morris Disability Questionnaire [28], the MOS 36-Item 
Short Form (SF-36) to assess functional health status and health-related quality of life [29], 
and reported on their current medication intake. A Medication Quantification Scale (MQS) 
score that represented total medication usage was calculated using weights assigned by 
medication class and dosage [30]. Participants completed the self-report inventories on the 
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first and last days of their participation in the pain management programme, based on their 
experiences over the previous week.  
 
Participants provided saliva samples on the three days immediately before participating in the 
pain management programme, and the three days immediately after completing the treatment.  
They were asked not to eat or drink anything containing caffeine or alcohol, or smoke 
cigarettes, in the 30 minutes before providing a sample because these substances may 
influence cortisol secretion directly, or might influence cortisol secretion indirectly by 
altering saliva pH [31-33].  Participants provided saliva samples four times each day: upon 
waking; late morning (11 a.m.); in the afternoon (4 p.m.); and just prior to going to bed (not 
later than 11 p.m.).  
 
Samples were collected using cotton dental rolls, which participants then placed in 5 mL 
plastic tubes with screw-capped lids and stored in their home freezer.  Samples were usually 
defrosted when delivered by participants to the experimenter at the hospital, but cortisol 
concentration in saliva samples is unlikely to deteriorate as a result of temporary defrosting 
[24, 34]. The samples were stored at approximately –20°C until the completion of the sample 
collection period.  They were then assayed by an enzyme-linked immunosorbent assay based 
on the general protocol of Elder and Lewis [35].  The cortisol conjugate used was 
hydrocortisone – 3 CMO-BSA; (Steraloids; Q3889); the primary antibody to cortisol was 
anticortisone (Sirosera; C336) and the secondary, enzyme-linked antibody was donkey-anti 
sheep-HRP (Sigma; A3415).  The intra and inter-assay coefficients of variation were 10.4% 
and 9.1% respectively.   
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The cortisol concentration data (in ng/mL) was log transformed prior to data reduction and 
statistical analysis to reduce the effect of outliers and to achieve adequate normality of the 
positively skewed data.  Changes from before to after treatment were investigated for each 
dependent variable with paired t-tests using the SPSS package (version 10). The association 
between the pre-to-post treatment change in log-transformed cortisol levels and change in 
psychometric ratings was investigated with Pearson’s correlation coefficient and partial 
correlation coefficients. All inferential statistics were two-tailed. 
 
RESULTS 
 
Mean ratings before and after treatment are shown in Table 1, and mean log-transformed 
cortisol levels before and after treatment are shown in Table 2.  Decreases in the Disability 
Quotient and increases in SF-36 scores (reflecting increases in health-related quality of life) 
indicate that the treatment was effective in these domains. Although depression, pain ratings 
and cortisol levels did not change significantly after treatment in the group as a whole, there 
was substantial variation among participants in all measures, particularly cortisol, both before 
and after treatment.  Inspection of the raw data indicated that many participants regularly 
experienced very high levels of cortisol, often with clear disruption of the expected diurnal 
pattern, while others experienced consistently low levels. Since pain and depression 
improved after treatment in some but not all cases, individual differences in cortisol levels 
before treatment, and changes following treatment, were explored in relation to depression 
and pain. 
   
Association between cortisol levels, pain and depression before treatment 
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Initial data analysis revealed an association between age and cortisol levels at each time of 
day (ranging from r=0.37 to 0.58).  Moreover, usual pain intensity was greater in older than 
younger participants [r(16)=0.60, p<0.01].  However, there was no association between 
medication consumption (as reflected by the MQS scores) and cortisol levels at any stage of 
the study. Therefore, only age was entered as a covariate in analyses that investigated the 
association between cortisol levels and other variables. As shown in Table 3, waking cortisol 
levels correlated strongly with pain ratings, but this relationship diminished to only a 
moderate relationship when the effect of age was removed [r(15)=0.39, not significant]. The 
relationship did not change when depression was entered as an additional covariate. Cortisol 
levels were not associated with depression at any time of day, either before or after usual pain 
intensity was entered as a covariate.  
 
Association between post-treatment changes in cortisol, pain and depression 
  
The change in cortisol levels from pre- to post-treatment was calculated separately for each of 
the times sampled during the day. Both before and after controlling for age, post-treatment 
changes in waking cortisol levels were associated with changes in pain (Table 4). As shown 
in Figure 1A, reductions in pain over the course of treatment were generally associated with 
reductions in waking cortisol levels. The relationship between post-treatment changes in 
waking cortisol levels and changes in usual pain intensity [r(16)=0.62, p<0.01] persisted after 
controlling for changes in depression [r(15)=0.63, p<0.01]. The relationship did not change 
after age was entered as an additional covariate [r(14)=0.56, p<0.05], but decreased after the 
most responsive patient was excluded from the analysis [r(13)=0.22, not significant].  
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Post-treatment reductions in late morning cortisol levels were generally associated with 
reductions in depression (Table 4 and Figure 1B). This effect persisted after controlling for 
changes in usual pain intensity [r(15)=0.60, p<0.05], and emerged for evening samples when 
age was entered as an additional covariate [for morning samples, r(14)=0.70, p<0.01; for 
evening samples, r(14)=0.69, p<0.01]. 
   
DISCUSSION 
 
This exploratory study produced a number of findings with interesting implications for 
understanding cortisol secretion in relation to usual pain intensity and mood in chronic pain 
patients.  In particular, an association between the usual intensity of chronic pain and salivary 
cortisol levels upon waking was detected. In addition, post-treatment changes in waking 
cortisol levels were associated with changes in usual pain intensity, as were post-treatment 
changes in late morning and evening cortisol levels and depression.   
 
Previous studies [5-8] differentiated between pain conditions of a mainly physical or 
psychosocial etiology on the basis of cortisol levels, and Shenkin [5] concluded that a low 
cortisol level was indicative of malingering.  However, the effects of pain intensity, 
venesection stress and mood on cortisol levels were not considered in these studies.  
Furthermore, the relationship between age and cortisol levels was overlooked, as was day-to-
day variation in cortisol.  We attempted to minimize the impact of these factors by sampling 
salivary cortisol several times per day for several days before and after patients participated 
in a pain management programme.  In addition, the relationship between cortisol levels, pain 
and depression was investigated independently of age.  The present findings indicated that an 
association between waking levels of cortisol and usual pain intensity was independent of 
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depression but was influenced by the participant’s age.  Cortisol levels varied widely between 
individuals and when measures were repeated in the same individual, both in the present 
study and in previous research [10].  Thus, it seems unlikely that psychosocial disorders such 
as malingering could be identified purely on the basis of the patient’s cortisol levels.  
 
Pain intensity was linked most closely with cortisol levels upon waking, possibly because 
cortisol begins to peak at this time of day or because of minimal interference by confounding 
factors such as daily hassles, eating, drinking, smoking and medication on cortisol and pain.  
A similar association between pain and waking levels of cortisol was identified recently by 
McLean et al. [36] in fibromyalgia patients.  Pain itself, or emotional responses to pain, may 
generate activity in the hypothalamic-pituitary-adrenal axis [4, 36].  Alternatively, neuro-
immune responses in the periphery associated with pain could stimulate cortisol release [37]. 
Cortisol might also influence pain intensity by acting on glucocorticoid receptors that interact 
with serotonergic or adrenergic pain modulation processes in the central nervous system [36]. 
An additional interesting possibility is that stress-related elevations in cortisol are involved in 
the pathogenesis of chronic pain – while in the short-term cortisol has anti-inflammatory 
properties, at chronically high levels cortisol has deleterious effects on the immune system 
[38], skeletal muscle tissue [39], and bone density [40, 41]. Thus, treatments that reduce 
stress-evoked elevations in cortisol might help to curb further physical deterioration in 
chronic pain patients.  
 
Hyperactivity of the hypothalamic-pituitary-adrenal axis is a feature of major depression [42], 
and may also be associated with negative affect in non-clinical samples. For example, 
Pruessner et al. [43] recently identified an association between depressive symptomatology 
and waking cortisol levels in healthy young men.  This association was not detected in the 
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present study, perhaps because ongoing pain or other factors (e.g., inflammation, medication 
or degenerative processes) also influenced cortisol secretion. Alternatively, the association 
may have been masked by heightened variability in cortisol levels at this time of day [44].    
 
Although cortisol secretion before the pain management programme was unrelated to levels 
of depression, changes in depression over the course of treatment were associated with 
changes in cortisol secretion in the morning and evening, independently of changes in pain.  
Similarly, changes in pain over the course of treatment were associated with changes in 
waking levels of cortisol secretion, independently of changes in depression.  In contrast to 
pain, the relationship between negative affect and cortisol secretion may strengthen during 
the day, due to the impact of daily hassles on mood.  Taken together, the findings suggest that 
investigating changes in cortisol levels within the same individual over time may be more 
useful than investigating individual differences in cortisol secretion at a single point in time, 
particularly in the context of treatment where reductions in usual pain intensity and 
improvements in mood may be associated with reductions in salivary cortisol levels. 
 
This study was limited by its small and heterogenous sample and its correlational design, and 
thus was exploratory in scope; hence, replication with more rigorous experimental controls 
and larger sample sizes would be required to minimize the impact of outliers and to identify 
causality in the relationships observed here.  To better understand the relationship between 
the immediate experience of pain and cortisol secretion, the association between salivary 
cortisol and momentary fluctuations in pain, mood, stress and anxiety in chronic pain patients 
should be explored more closely [45].  This is of particular interest given the frequent 
aberrant deviations from the expected pattern of diurnal variation observed in many of the 
participants in the present study.  
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Despite the limitations of this research, the present findings provide preliminary evidence of a 
relationship between waking cortisol levels and usual pain intensity, independent of 
depression.  This relationship appeared to be stronger within than between individuals, 
presumably because psychological or physiological factors that influence pain ratings and 
cortisol secretion masked the association when investigated across the study population.  The 
findings suggest that changes in cortisol secretion may provide a useful biological marker of 
treatment outcome in chronic pain patients, both in terms of mood change and change in 
usual pain intensity.   
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Table 1: Results of psychometric outcome measures pre- and post-treatment (n=18). 
 Psychometric       Pre-treatment       Post-treatment t-test Sig. 
 Instrument Mean SD Mean SD     
 ZSDS 31.22 14.31 28.78 12.3 1.08 0.296 
 NGRS 5.17 1.79 4.06 1.73 1.99 0.063 
SF-36 321 160 395 151 2.97 0.009* 
DQ 10.00 4.60 7.44 5.14 2.95 0.009* 
MQS 8.71 11.92 6.65 8.78 1.73 0.103 
ZSDS: Zung Self-Rating Depression Scale; NGRS: a 0-10 Numerical Graphic Rating Scale 
of average pain perception intensity; SF-36: MOS 36-Item Short Form; DQ: Disability 
Quotient; MQS: Medication Quantification Scale. 
* statistically significant (p<0.05) after applying the Bonferroni correction for multiple 
comparisons across the five dependent variables. 
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Table 2: Log-transformed cortisol concentrations (initially measured in ng/mL) pre- and post-
treatment (n=18). 
 Sample Collection       Pre-treatment       Post-treatment t-test Sig. 
 Time Mean S.E. Mean S.E.    
  Wake 1.12 .12 1.07 .11 .40  0.70 
  Late morning .72 .14 .73 .16 .06 0.96 
  Late afternoon .73 .15 .57 .14 1.31  0.21 
  Bedtime .50 .17 .47 .19 .23 0.82 
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Table 3:  Pearson’s correlation coefficient between pain, depression 
and pre-treatment levels of cortisol 
 Cortisol (Time of Sampling) 
  Wake Late Morning Late Afternoon Bedtime 
ZSDS -0.27 -0.38  -0.45  -0.38  
NGRS 0.59** 0.25 0.30 0.45 
  
ZSDS: Zung Self-Rating Depression Scale; NGRS: a 0-10 Numerical Graphic Rating Scale 
of average pain perception intensity. 
** p<0.01; statistically significant (p<0.05) after applying the Bonferroni correction for 
multiple comparisons across the two dependent variables, or across the four time points 
within each dependent variable. 
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Table 4:  Pearson’s correlation coefficient between post-treatment changes in cortisol levels and 
changes in pain and depression 
 Cortisol (Time of Sampling) 
  Wake Late Morning Late Afternoon Bedtime 
ZSDS 0.12 0.60**  0.11  0.43  
NGRS 0.62** 0.16 0.11 0.04 
  
ZSDS: Zung Self-Rating Depression Scale; NGRS: a 0-10 Numerical Graphic Rating Scale 
of average pain perception intensity. 
** p<0.01; statistically significant (p<0.05) after applying the Bonferroni correction for 
multiple comparisons across the two dependent variables, or across the four time points 
within each dependent variable. 
 
 23 
Figure legend 
 
Figure 1. Relationship between changes in pain and waking cortisol (A), and depression and 
morning cortisol (B), over the course of treatment. Reductions following treatment were 
calculated by subtracting post-treatment levels from pre-treatment levels.
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